127 related articles for article (PubMed ID: 17627611)
1. Assessment of 11C-labeled-4-N-(3-bromoanilino)-6,7-dimethoxyquinazoline as a positron emission tomography agent to monitor epidermal growth factor receptor expression.
Wang H; Yu J; Yang G; Song X; Sun X; Zhao S; Mu D
Cancer Sci; 2007 Sep; 98(9):1413-6. PubMed ID: 17627611
[TBL] [Abstract][Full Text] [Related]
2. Further characterization of the epidermal growth factor receptor ligand 11C-PD153035.
Wang H; Yu JM; Yang GR; Song XR; Sun XR; Zhao SQ; Wang XW; Zhao W
Chin Med J (Engl); 2007 Jun; 120(11):960-4. PubMed ID: 17624262
[TBL] [Abstract][Full Text] [Related]
3. Metabolism of epidermal growth factor receptor targeting probe [11C]PD153035: impact on biodistribution and tumor uptake in rats.
Samén E; Arnberg F; Lu L; Olofsson MH; Tegnebratt T; Thorell JO; Holmin S; Stone-Elander S
J Nucl Med; 2013 Oct; 54(10):1804-11. PubMed ID: 24003078
[TBL] [Abstract][Full Text] [Related]
4. Predictive efficacy of (11)C-PD153035 PET imaging for EGFR-tyrosine kinase inhibitor sensitivity in non-small cell lung cancer patients.
Dai D; Li XF; Wang J; Liu JJ; Zhu YJ; Zhang Y; Wang Q; Xu WG
Int J Cancer; 2016 Feb; 138(4):1003-12. PubMed ID: 26334931
[TBL] [Abstract][Full Text] [Related]
5. [Molecular imaging of epidermal growth factor receptor in glioma-bearing rats].
Wang H; Yu JM; Song XR; Yang GR; Mu DB; Zhao SQ; Wang XW; Wei L; Liu YL; Song B; Fu Z; Teng XP
Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):343-6. PubMed ID: 18953832
[TBL] [Abstract][Full Text] [Related]
6. A pilot study on EGFR-targeted molecular imaging of PET/CT With 11C-PD153035 in human gliomas.
Sun J; Cai L; Zhang K; Zhang A; Pu P; Yang W; Gao S
Clin Nucl Med; 2014 Jan; 39(1):e20-6. PubMed ID: 24335566
[TBL] [Abstract][Full Text] [Related]
7. In vivo evaluation of the biodistribution of 11C-labeled PD153035 in rats without and with neuroblastoma implants.
Fredriksson A; Johnström P; Thorell JO; von Heijne G; Hassan M; Eksborg S; Kogner P; Borgström P; Ingvar M; Stone-Elander S
Life Sci; 1999; 65(2):165-74. PubMed ID: 10416822
[TBL] [Abstract][Full Text] [Related]
8. PET-based biodistribution and radiation dosimetry of epidermal growth factor receptor-selective tracer 11C-PD153035 in humans.
Liu N; Li M; Li X; Meng X; Yang G; Zhao S; Yang Y; Ma L; Fu Z; Yu J
J Nucl Med; 2009 Feb; 50(2):303-8. PubMed ID: 19164239
[TBL] [Abstract][Full Text] [Related]
9. Molecular imaging with 11C-PD153035 PET/CT predicts survival in non-small cell lung cancer treated with EGFR-TKI: a pilot study.
Meng X; Loo BW; Ma L; Murphy JD; Sun X; Yu J
J Nucl Med; 2011 Oct; 52(10):1573-9. PubMed ID: 21903741
[TBL] [Abstract][Full Text] [Related]
10. Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts.
Memon AA; Jakobsen S; Dagnaes-Hansen F; Sorensen BS; Keiding S; Nexo E
Cancer Res; 2009 Feb; 69(3):873-8. PubMed ID: 19155297
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and initial tumor affinity testing of iodine-123 labelled EGFR-affine agents as potential imaging probes for hormone-refractory prostate cancer.
Fozing T; Scheuer C; Samnick S
Eur J Med Chem; 2010 Sep; 45(9):3780-6. PubMed ID: 20538380
[TBL] [Abstract][Full Text] [Related]
12. Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imgatuzumab.
Pool M; Kol A; Lub-de Hooge MN; Gerdes CA; de Jong S; de Vries EG; Terwisscha van Scheltinga AG
Oncotarget; 2016 Oct; 7(42):68111-68121. PubMed ID: 27602494
[TBL] [Abstract][Full Text] [Related]
13.
Kwon LY; Scollard DA; Reilly RM
Mol Pharm; 2017 Feb; 14(2):492-501. PubMed ID: 28049295
[TBL] [Abstract][Full Text] [Related]
14. The DNA-binding epidermal growth factor-receptor inhibitor PD153035 and other DNA-intercalating cytotoxic drugs reactivate the expression of the retinoic acid receptor-beta tumor-suppressor gene in breast cancer cells.
Grunt TW; Tomek K; Wagner R; Puckmair K; Zielinski CC
Differentiation; 2007 Nov; 75(9):883-90. PubMed ID: 17608728
[TBL] [Abstract][Full Text] [Related]
15. Immuno-PET imaging for non-invasive assessment of cetuximab accumulation in non-small cell lung cancer.
Yamaguchi A; Achmad A; Hanaoka H; Heryanto YD; Bhattarai A; Ratianto ; Khongorzul E; Shintawati R; Kartamihardja AAP; Kanai A; Sugo Y; S Ishioka N; Higuchi T; Tsushima Y
BMC Cancer; 2019 Oct; 19(1):1000. PubMed ID: 31651282
[TBL] [Abstract][Full Text] [Related]
16. Development of [
Cavaliere A; Sun S; Lee S; Bodner J; Li Z; Huang Y; Moores SL; Marquez-Nostra B
Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):383-394. PubMed ID: 32770372
[TBL] [Abstract][Full Text] [Related]
17. Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer.
McKnight BN; Kim S; Boerner JL; Viola NT
Breast Cancer Res; 2020 Apr; 22(1):37. PubMed ID: 32295603
[TBL] [Abstract][Full Text] [Related]
18. PET imaging of EGFR expression in nude mice bearing MDA-MB-468, a human breast adenocarcinoma.
Sadri K; Ren Q; Zhang K; Paudyal B; Devadhas D; Rodeck U; Thakur M
Nucl Med Commun; 2011 Jul; 32(7):563-9. PubMed ID: 21572364
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of gefitinib sensitivity with radioiodinated PHY based on EGFR expression.
Yoshimoto M; Hirata M; Kanai Y; Naka S; Nishii R; Kagawa S; Kawai K; Ohmomo Y
Biol Pharm Bull; 2014; 37(3):355-60. PubMed ID: 24583857
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
